Nothing Special   »   [go: up one dir, main page]

BRPI0620659A2 - método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica - Google Patents

método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica

Info

Publication number
BRPI0620659A2
BRPI0620659A2 BRPI0620659A BRPI0620659A BRPI0620659A2 BR PI0620659 A2 BRPI0620659 A2 BR PI0620659A2 BR PI0620659 A BRPI0620659 A BR PI0620659A BR PI0620659 A BRPI0620659 A BR PI0620659A BR PI0620659 A2 BRPI0620659 A2 BR PI0620659A2
Authority
BR
Brazil
Prior art keywords
oxidative stress
neurodegenerative disease
individual
individual afflicted
onset
Prior art date
Application number
BRPI0620659A
Other languages
English (en)
Inventor
Weinstock-Rosin Marta
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of BRPI0620659A2 publication Critical patent/BRPI0620659A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0620659A 2005-12-09 2006-12-08 método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica BRPI0620659A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74874805P 2005-12-09 2005-12-09
US79241006P 2006-04-17 2006-04-17
PCT/US2006/047038 WO2007070425A2 (en) 2005-12-09 2006-12-08 Use of low-dose ladostigil for neuroprotection

Publications (1)

Publication Number Publication Date
BRPI0620659A2 true BRPI0620659A2 (pt) 2017-10-31

Family

ID=38163442

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620659A BRPI0620659A2 (pt) 2005-12-09 2006-12-08 método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica

Country Status (10)

Country Link
US (2) US8420696B2 (pt)
EP (1) EP1956904B1 (pt)
JP (1) JP2009518433A (pt)
CN (2) CN103142570A (pt)
AU (1) AU2006326642B2 (pt)
BR (1) BRPI0620659A2 (pt)
CA (1) CA2634166C (pt)
ES (1) ES2632638T3 (pt)
IL (1) IL191859A (pt)
WO (1) WO2007070425A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006216509B8 (en) 2005-02-24 2012-11-01 Technion Research And Development Foundation Ltd Formulations of ladostigil tartrate
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691A1 (en) * 2006-03-31 2007-10-04 Tamar Goren Use of ladostigil for the treatment of schizophrenia
WO2012059920A1 (en) * 2010-11-02 2012-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigil dosage regime
EP2811995B1 (en) 2012-02-12 2017-08-09 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Ladostigil therapy for immunomodulation
EP3976188A1 (en) * 2019-05-28 2022-04-06 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions for delivery of ladostigil

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2916490A (en) * 1959-12-08 Ocjhs
US2982783A (en) * 1961-05-02 Amevoevdanes
US3201470A (en) * 1965-08-17 Chsx c cech
US3123642A (en) * 1964-03-03 Indanyl and tetrahydronaphthyl
SE371190B (pt) * 1972-03-24 1974-11-11 Kabi Ab
US2573645A (en) * 1949-05-25 1951-10-30 Smith Kline French Lab N-hydroxyethyl aminoindanes
GB852735A (en) 1956-04-13 1960-11-02 Schering Ag Manufacture of 1-aminoindanes
US3178478A (en) * 1961-02-13 1965-04-13 Ciba Geigy Corp 2-amino-5-halo-indanes
US3060091A (en) * 1961-02-13 1962-10-23 Ciba Geigy Corp Analgesic composition consisting of morphines and amino-indanes
US3253037A (en) * 1962-06-19 1966-05-24 Ciba Geigy Corp N-2-alkynyl-amino-benzocylo-alkanes
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US3709996A (en) * 1963-08-02 1973-01-09 Aspro Nicholas Ltd Pharmaceutical compositions containing n-cyclopropyl-1-aminoindane compounds and adapted for administration to obtain inhibition of monoamine oxidase enzyme and process
NL6408165A (pt) * 1964-07-17 1966-01-18
US3308157A (en) * 1964-08-07 1967-03-07 Colgate Palmolive Co N-(benzocyclobutene-1-loweralkyl)-carboxylic acid amides
US3637740A (en) * 1969-04-21 1972-01-25 Pfizer Aminobenzocycloalkane compounds
US3507962A (en) * 1969-05-09 1970-04-21 Thompson Chem Co Hayward Controlling leafminer insects with selected carbamate insecticides,including 3,5-dimethyl-4-dimethylamino-methyl phenyl-n-methylcarbamate
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
NL7011683A (pt) * 1970-08-07 1972-02-09
US3991207A (en) * 1971-03-18 1976-11-09 Pfizer Inc. Combination therapy for Parkinson's disease
US3751420A (en) * 1971-04-01 1973-08-07 Squibb & Sons Inc Monoolmonoene amines
BE786748A (fr) * 1971-07-26 1973-01-26 Basf Ag 1-aminomethyl-indanes-n-substitues
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds
US4134997A (en) * 1977-03-01 1979-01-16 University Of Iowa Research Foundation Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts
US4096173A (en) * 1977-03-28 1978-06-20 Eli Lilly And Company Chlorinated 1-aminoindane N-methyl transferase inhibitors
US4128666A (en) * 1977-08-18 1978-12-05 Smithkline Corporation 4 AND 5-Halo substituted 2-indanamine compounds
US4132737A (en) * 1978-02-27 1979-01-02 Eli Lilly And Company Trifluoromethyl substituted 1-aminoindanes
US5286747A (en) * 1981-05-08 1994-02-15 Per A. E. Carlsson 1-alkyl-2-aminotetralin derivatives
SE464194B (sv) * 1983-03-04 1991-03-18 Otsuka Pharma Co Ltd Indanderivat, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner
US4529723A (en) * 1983-04-29 1985-07-16 William H. Rorer, Inc. Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use
JPS6169747A (ja) * 1984-08-31 1986-04-10 Otsuka Pharmaceut Co Ltd ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法
US5242919A (en) * 1984-08-31 1993-09-07 Otsuka Pharmaceutical Co., Ltd. 2,3-dihydro-1H-indene derivatives
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
US4632939A (en) * 1985-03-15 1986-12-30 Eli Lilly And Company Anticonvulsant agents
US4833273A (en) * 1986-02-03 1989-05-23 Warner-Lambert Company Process for the resolution of 1-aminoindanes
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US5153225A (en) * 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5011995A (en) * 1987-07-28 1991-04-30 Ciba-Geigy Corporation Process for the preparation of optically active secondary amines
US4873241A (en) * 1988-10-31 1989-10-10 Fisons Corporation 2-amino-N-(2-phenylindan-2-yl)acetamides useful as anti-epileptics
US5225596A (en) * 1989-01-09 1993-07-06 The Upjohn Company Halo substituted aminotetralins
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
JP2725378B2 (ja) 1989-05-29 1998-03-11 武田薬品工業株式会社 カルバミド酸エステル誘導体
IE902294A1 (en) 1989-07-06 1991-01-16 Abbott Lab Alkynyl amines that regulate cholinergic neurotransmission
US5118704A (en) * 1989-08-30 1992-06-02 Whitby Research, Inc. Substituted 2-aminotetralins useful as dopaminergics
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
JPH03176457A (ja) * 1989-12-04 1991-07-31 Nippon Paint Co Ltd 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
FR2662162B1 (fr) * 1990-05-18 1995-01-20 Adir Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
TW197435B (pt) * 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
ATE194837T1 (de) 1992-10-05 2000-08-15 Ube Industries Pyridmidin-derivate
US5350762A (en) 1993-03-08 1994-09-27 Hoechst-Roussel Pharmaceuticals Incorporated Tetrahydrocyclopent[B]indole methanamines and related compounds
GB9315600D0 (en) 1993-07-28 1993-09-08 Smithkline Beecham Plc Compounds
ATE187436T1 (de) * 1993-08-06 1999-12-15 Upjohn Co 2-aminoindane als selektive dopamin-d3-liganden
US5516943A (en) * 1993-09-14 1996-05-14 Sepracor, Inc. Process for preparing cyclic CIS-1-amino-2-alkanols
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
FR2717175B1 (fr) * 1994-03-11 1996-06-14 Adir Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US5646188A (en) * 1995-07-05 1997-07-08 Teva Pharmaceutical Industries, Ltd. Polyamine derivatives of 1-aminoindan
DE19529604A1 (de) 1995-08-11 1997-02-13 Bayer Ag Endoparasitizide Mittel auf Basis von Didepsipeptiden, neue Didepsipeptide und ein Verfahren zu ihrer Herstellung
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
US6251938B1 (en) * 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
EP1535902B1 (en) * 1996-12-18 2007-11-07 Teva Pharmaceutical Industries, Ltd. Aminoindan derivatives
ES2208967T3 (es) 1996-12-18 2004-06-16 Teva Pharmaceutical Industries, Ltd. Derivados de feniletilamina.
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
CA2547053C (en) * 2003-11-25 2014-05-27 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US20050267077A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function by co-administration of a GABAB receptor antagonist and an acetylcholinesterase inhibitor
CN101128420A (zh) * 2005-02-24 2008-02-20 泰华制药工业有限公司 拉多斯迪戈酒石酸盐结晶体、其制备方法及其药物组合物
AU2006216509B8 (en) * 2005-02-24 2012-11-01 Technion Research And Development Foundation Ltd Formulations of ladostigil tartrate
WO2006130726A2 (en) * 2005-06-01 2006-12-07 Teva Pharmaceutical Industries, Ltd. Use of ladostigil for the treatment of multiple sclerosis
US20070135518A1 (en) * 2005-12-09 2007-06-14 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20070232691A1 (en) * 2006-03-31 2007-10-04 Tamar Goren Use of ladostigil for the treatment of schizophrenia

Also Published As

Publication number Publication date
IL191859A (en) 2014-08-31
US20070293583A1 (en) 2007-12-20
WO2007070425A3 (en) 2008-02-21
AU2006326642A1 (en) 2007-06-21
EP1956904B1 (en) 2017-04-12
AU2006326642B2 (en) 2012-05-03
CA2634166A1 (en) 2007-06-21
EP1956904A4 (en) 2010-08-18
ES2632638T3 (es) 2017-09-14
US8420696B2 (en) 2013-04-16
CN101325871A (zh) 2008-12-17
WO2007070425A2 (en) 2007-06-21
US20130150438A1 (en) 2013-06-13
EP1956904A2 (en) 2008-08-20
IL191859A0 (en) 2009-02-11
JP2009518433A (ja) 2009-05-07
CN103142570A (zh) 2013-06-12
CN101325871B (zh) 2013-04-10
CA2634166C (en) 2016-03-29

Similar Documents

Publication Publication Date Title
BRPI0620659A2 (pt) método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
BRPI0810561A2 (pt) métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13.
BRPI0915986A2 (pt) composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
CL2008003316A1 (es) Forma cristalina vi de la agomelatina; procedimientos de preparacion; composicion farmaceutica, util para el tratamiento de estres, ansiedad, depresion mayor, ataques de panico, enfermedad de parkinson, epilepsia, enfermedad de alzheimer.
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0719912A2 (pt) Método para tratar lupus eritematoso sistêmico, e, método para reduzir elevações passageiras de índice de atividade da doença lupus eritematoso sistêmico
MY169492A (en) Improved protofibril selective antibodies and the use thereof
BRPI0611059A2 (pt) espaçador intra-espinhal para implantação entre processos espinhais da espinha e método para fabricar o mesmo
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
IL181061A0 (en) Pharmaceutical compositions for preventing and treating diseases characterized by lewy bodies or alpha-synuclein aggregation in the brain
CL2007003640A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0918194A2 (pt) ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BRPI0822162A2 (pt) Método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal.
BRPI0810081A2 (pt) Agente terapêutico e agente diagnóstico para doenças cerebrais de disfunção mitocondrial
BRPI1005153A2 (pt) composto, composição farmacêutica, uso de um composto, metodo para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
BR122019016628B8 (pt) uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular
HK1115341A1 (en) Composition for treating mental health disorders
BRPI0619853A2 (pt) combinação, composição farmacêutica, e, métodos de antagonização da atividade biológica, de tratamento de angiogênese relacionada à doença em um mamífero e de tratamento de câncer em um mamífero
EP1923388A4 (en) BRAIN / NERVE CELL PROTECTION AND THERAPEUTIC FOR SLEEP DISORDERS
BRPI0510274A (pt) epìtopos relacionados à doença celìaca
BRPI1016185A2 (pt) processo para o tratamento de distúrbios associados à atividade da proteína quinase ck2
HK1118716A1 (en) Method and composition for treating central nervous system disorders

Legal Events

Date Code Title Description
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: REFERENTE A PETICAO NO 18100007879/SP DE 08.03.2010, DE ACORDO COM O INCISO II, ARTIGO 219 DA LPI 9279/96.

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements